Search research articles
Contact Us
Filters
Showing results (191-200 of 266) with videos related to
Page
of 27
Sort By:
Cancer Immunology, Immunotherapy : CII
|
August 29, 2013
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1
Yibing Xu, Jianping Sun, Michael A Sheard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study
M F Ozkaynak, P M Sondel, M D Krailo, et al.
Medical and Pediatric Oncology
|
December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma
L M Choi, N W Kim, J J Zuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
K K Matthay, K DeSantes, B Hasegawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2019
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Hong-Wei Wu, Michael A Sheard, Jemily Malvar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study
C A Perez, K K Matthay, J B Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results
K K Matthay, M C O'Leary, N K Ramsay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1988
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
G M Brodeur, R C Seeger, A Barrett, et al.
Cancer Research
|
May 2, 2013
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma
Tasnim Ara, Rie Nakata, Michael A Sheard, et al.
Progress in Clinical and Biological Research
|
January 1, 1988
International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma
G M Brodeur, R C Seeger, A Barrett, et al.
Page
of 27
Search research articles
Search
Showing results (191-200 of 266) with videos related to
Sort By:
Page
of 27
Cancer Immunology, Immunotherapy : CII
|
August 29, 2013
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1
Yibing Xu, Jianping Sun, Michael A Sheard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2000
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study
M F Ozkaynak, P M Sondel, M D Krailo, et al.
Medical and Pediatric Oncology
|
December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma
L M Choi, N W Kim, J J Zuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
K K Matthay, K DeSantes, B Hasegawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2019
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Hong-Wei Wu, Michael A Sheard, Jemily Malvar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study
C A Perez, K K Matthay, J B Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results
K K Matthay, M C O'Leary, N K Ramsay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1988
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma
G M Brodeur, R C Seeger, A Barrett, et al.
Cancer Research
|
May 2, 2013
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma
Tasnim Ara, Rie Nakata, Michael A Sheard, et al.
Progress in Clinical and Biological Research
|
January 1, 1988
International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma
G M Brodeur, R C Seeger, A Barrett, et al.
Page
of 27